Press Releases

12/20/2006
Labopharm submits response to approvable letter for once-daily Tramadol to FDA

11/2/2006
Labopharm reports results for third quarter fiscal 2006

10/31/2006
Labopharm to Present at CIBC World Markets 17th Annual Healthcare Conference in New York

10/25/2006
Labopharm To Host Conference Call Thursday, November 2, 2006 at 8:30 A.M. (ET)

9/29/2006
Labopharm receives approvable letter from FDA for once-daily tramadol

9/13/2006
Labopharm Appoints Mark D'Souza as Chief Financial Officer

9/8/2006
Labopharm to Present Safety Data from U.S. Phase III Trials for Once-Daily Tramadol at Clinical Meeting of American Academy of Pain Management

8/28/2006
Labopharm's New Drug Submission for Once-Daily Tramadol Accepted for Review by Health Canada

8/8/2006
Labopharm Reports Results for Second Quarter Fiscal 2006

8/4/2006
Labopharm to Present at Bank of America 2006 Specialty Pharmaceuticals Conference in Southampton, New York

7/25/2006
Labopharm To Host Conference Call Tuesday, August 8, 2006 at 8:30 A.M. (ET)

7/7/2006
Labopharm to Present at Leerink Swann & Company/MEDACorp Pain Roundtable Conference in New York City

6/16/2006
Labopharm to Present at the Orion Healthcare Conference

5/31/2006
Labopharm Expands Relationship with GSK for Once-Daily Tramadol to Include Mexico

5/30/2006
Labopharm to Speak at Canaccord Adams Life Sciences Conference

5/15/2006
Labopharm to Present at Bank of America Healthcare Conference

5/9/2006
Labopharm Enters Into Distribution Agreement with Grunenthal for Once-Daily Tramadol in Belgium

5/4/2006
Labopharm appoints Santo J. Costa to chairman of the Board

5/3/2006
Labopharm completes public offering for estimated net proceeds of US$93.3 million (CDN$104.8 million), including exercise of over-allotment option

4/28/2006
Labopharm announces pricing of public offering

4/25/2006
Labopharm reports results for first quarter fiscal 2006

4/18/2006
Labopharm files preliminary prospectus for cross-border offering of 10 million common shares

4/12/2006
Labopharm Reports Positive Results for Phase III Study on Once-Daily Tramadol

3/2/2006
Labopharm appoints Santo J. Costa to Board of Directors

2/16/2006
Labopharm Reports Results for Fourth Quarter Fiscal 2005

2/9/2006
Labopharm To Host Conference Call Thursday, February 16, 2006 At 8:30 A.M. (ET)

1/31/2006
Labopharm to present at Merrill Lynch global healthcare conference in New York

1/30/2006
Labopharm Adds Grunenthal as Second Marketing Partner for Once-Daily Tramadol in France

1/30/2006
Labopharm's Once-Daily Tramadol NDA Accepted for Review by U.S. FDA